Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Acquisitions & Divestments (2018 - 2025)

Historic Change in Acquisitions & Divestments for Viridian Therapeutics, Inc.\DE (VRDN) over the last 8 years, with Q3 2025 value amounting to $140.3 million.

  • Viridian Therapeutics, Inc.\DE's Change in Acquisitions & Divestments fell 260.89% to $140.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $562.2 million, marking a year-over-year increase of 2471.08%. This contributed to the annual value of $466.9 million for FY2024, which is 4845.45% up from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Change in Acquisitions & Divestments is $140.3 million, which was down 260.89% from $131.5 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Change in Acquisitions & Divestments' 5-year high stood at $171.4 million during Q1 2025, with a 5-year trough of -$497000.0 in Q2 2021.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $67.5 million (2021), whereas its average is $76.2 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Change in Acquisitions & Divestments soared by 327695.0% in 2021, and later tumbled by 7892.48% in 2022.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Change in Acquisitions & Divestments (Quarter) stood at $22.8 million in 2021, then soared by 65.67% to $37.7 million in 2022, then skyrocketed by 172.76% to $102.8 million in 2023, then rose by 15.7% to $119.0 million in 2024, then rose by 17.91% to $140.3 million in 2025.
  • Its last three reported values are $140.3 million in Q3 2025, $131.5 million for Q2 2025, and $171.4 million during Q1 2025.